Future and Economics of Nuclear Medicine

Need to understand future and economics of Nuclear Medicine? Looking for experts in this field? Trying to appreciate the potential of this new technology?

MEDraysintell will display its series of market reports and directories with over 2,100 pages of unrivaled intelligence covering Nuclear Medicine, Cyclotrons, Brachytherapy and Proton Therapy, during the EANM – European Association of Nuclear Medicine – congress (Vienna, Austria, October 21-25, 2017). MEDraysintell is gratefully hosted by the company ANMI and visitors are welcome at booth 318.

With the recent official approval of 177Lu-Lutathera by EMA for the European market, triggering further the interest of big pharmas for Advanced Accelerator Applications, and the 177Lu-PSMA-617 rights licensed by Endocyte from ABX, it is now obvious that nuclear medicine and in particular its therapeutic potential becomes of high priority for new investors. Radiotherapeutics will soon become part of their portfolio at the same level if not more efficient than chemotherapies.

In the past few months several other key events have confirmed the trend of an increasing interest for the nuclear medicine market, such as Jubilant Pharma acquiring Triad Isotopes, Sofie Biosciences purchasing Zevacor Pharma, Theragnostics Ltd. partnering with ROTOP Pharmaka, ARTMS Products and GE Healthcare teaming up on cyclotron targets, Telix Pharma and CellSight concluding license agreement or Konica Minolta taking over InviCRO.

Radiotherapeutics are multiplying the prospects for profitability and thus attract several major investors and in particular conventional pharmaceutical companies which have started showing a stronger interest over the last few years, a trend that will definitely increase in the near future. Additionally, by linking radiodiagnostics to radiotherapeutics, this technology demonstrated clearly the concept of Theranostics. Imaging allows selecting the positive responders and the follow-up therapy with an analogue therapeutic molecule increases dramatically the efficacy of treatment in this well-defined sub-group of patients.

A growing number of companies, often start-ups, are developing radiopharmaceuticals on this basis and will soon need to link with larger partners and/or investors.

MEDraysintell reports and directories are becoming the sole trusted sources of intelligence in the radiation healthcare industry. Reports can be customized to specific areas or modalities. Sample pages and complete table of contents are available upon request. MEDraysintell also welcomes your requests for specific intelligence needs in these areas.

We look forward to seeing you in Vienna!

About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 2,100 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com

MEDraysintell
Chemin du Cyclotron 6
1348 Louvain-la-Neuve, Belgium
Paul-Emmanuel Goethals, MBA
e-Mail: peg@medraysintell.com
Mobile: +32 491 080 968

This release was published on openPR.